[01] Hamid Yahya Hussain, Dubai Health Authority, Dubai, United Arab Emirates. [02] Nezar Ahmed Salim, Dubai Hospital, Dubai Health Authority, Dubai, United Arab Emirates. [03] Mohammed Ghassan Tuffaha, Amana Health Care Medical and Rehabilitation Hospital, Abu Dubai, United Arab Emirates. [04] Ahmed Yahya Ayoub, Al Dafrah Hospitals, Madinate Zayed Hospital, Abu Dhabi, United Arab Emirates.

Background: Hypertension is a strong risk factor for cardiovascular as well as renal and neurological disorders. Objectives: To study hypertension profile among Dubai population, to link hypertension risk to cardiovascular morbidities Methodology: Across-sectional, cluster stratified sample of 1984 individual selected randomly and responded, as part of Dubai health survey setting carried out in emirate of Dubai 2019, different age, gender and nationalities as members of visited families, or visited labor camps from 6^th Feb-29 of March 2019, interviewed by data collection questionnaire as well as exposed to three-time measuring and reporting of blood pressure both systolic and diastolic blood pressure by highly trained (25) nurses from Dubai Health authority, at individuals and families houses, sphygmomanometer used were adequately caliber and checked out data directly administered to the electronic questionnaire on IPad equipment’s connected to Dubai statistics center collecting point, for auditing, quality checking and adding to statistical database of the health survey, data entry, data coding, data cleaning, weighing and data analysis using Stata 12 version software. American heart association operational definitions and cut off points has been utilized (as for diastolic blood pressure considered being first stage hypertension in BP (80-90) second stage diastolic hypertension (>100MH) as for systolic blood, pressure (130-139) considered as first stage systolic hypertension, (>14) second stage hypertension Findings: The study revealed that the total prevalence of diastolic hypertension was 41.90% of the totalsample, while total prevalence of systolic hypertension was 34%, First stage systolic hypertension in the first reading was 18.1% while the second stage hypertension was 18.2%, study showed as well that first stage Diastolic hypertension first measurement was 28.5% while second stage hypertension was 17.4%, The existing study reflected that the third measurement, first stage hypertension was 16.6% while second stage hypertension was 17.4%, In addition, the diastolic hypertension first stage in the third measurement was 29.0% and second stage hypertension was 12.7%, the study showed that more than 50% of systolic hypertension was among younger age groups below 40 years old. Conclusions: The vast majority of sample have normal blood pressure. On the other hand, the prevelance of “Stage 1 systolic hypertension” and “Stage 2 systolic hypertension” were higher among the group age 18-29 years compared to other age group. such high impact factor will stand as strong risk for cardiovascular morbidities and mortalities consequences for a big segment of population, will put more burdens and pressures upon services demand, expenditure and health system.

Hypertension, Dubai Population, Risk Analysis, Survey Data

[01] World Health Organization. World Health Day 2013. A global brief on hypertension. Silent killer, global public health crisis. [Cited 2018 August 5]. Available at: https://apps.who.int/iris/bitstream/handle/10665/79059/WHO_DCO_WHD_2013.2_eng.pdf;jsessionid=7E885%200A9D7250A82EDCAC9492B848ED?sequence=1. [02] World Health Organization. Global status report on noncommunicable diseases 2010. Geneva, World Health Organization, 2011. [cited 2018 August 5]. Available at: http://www.who.int/nmh/publications/ncd_report2010/en/. [03] World Health Organization. Global Health Observatory Data Repository [online database]. Geneva, World Health Organization, 2008. [cited 2018 August 5]. Available at: https://www.who.int/gho/en/. [04] Abd El-Aty, M. A., Meky, F. A., Morsi, M. M., Al-Lawati, J. A., El Sayed, M. K. (2015). Hypertension in the adult Omani population: predictors for unawareness and uncontrolled hypertension. J Egypt Public Health Assoc.; 90 (3): 125-32. doi: 10.1097/01.EPX.0000470547.32952.cf. [05] Al-Zakwani, I., Al-Hashmi, Kh. (2018). Hypertension in Oman: Where Do We Stand? Oman Med J; 33 (5): 365–366. doi: 10.5001/omj.2018.68. [06] Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ 2009 May; 338: b1665. [07] Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. J Hypertens2007; 25:1105-87. [08] Almahrezi A, Al-Zakwani I, Al-Aamri A, Al-Khaldi S, Al-Zadjali N, Al-Hatali M, et al. Control and management of hypertension at a university health centre in oman. Sultan Qaboos Univ Med J 2008 Jul; 8 (2): 179-184. [09] Al-Shidhani TA, Bhargava K, Rizvi S. An audit of hypertension at university health center in oman. Oman Med J 2011 Jul; 26 (4): 248-252. [10] Al-Saadi R, Al-Shukaili S, Al-Mahrazi S, Al-Busaidi Z. Prevalence of uncontrolled hypertension in primary care settings in Al seeb wilayat, oman. Sultan Qaboos Univ Med J 2011 Aug; 11 (3): 349-356. [11] Al-Zakwani I, Al-Mahmeed W, Arafah M, Al-Hinai AT, Shehab A, Al-Tamimi O, et al. Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf. Curr Vasc Pharmacol 2016; 14 (4): 374-381. [12] El-Shafie K, Rizvi S. Control of Hypertension among Type II Diabetics. Oman Med J 2010 Jan; 25 (1): 32-36. [13] Degli Esposti L, Di Martino M, Saragoni S, Sgreccia A, Capone A, Buda S, et al. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens (Greenwich). 2004 Feb; 6 (2):76-84. [14] Tobe SW, Lewanczuk R. Resistant hypertension. Can J Cardiol. 2009 May; 25 (5): 315-7. doi: 10.1016/s0828-282x(09)70496-9. PMID: 19417863; PMCID: PMC2707174. [15] Zubaid, M., Suresh, C. G., Thalib, L., Rashed, W. (2004). Differential Distribution of Risk Factors and Outcome of Acute Coronary Syndrome in Kuwait: Three Years’ Experience. Med Princ Pract; 13: 63-68. https://doi.org/10.1159/000075630. [16] Suresh CG, Zubaid M, Thalib L, Rashed W, David T. Racial variation in risk factors and occurrence of acute myocardial infarction: comparison between Arab and South Asian men in Kuwait. Indian Heart J 2002; 54: 266-270. [17] Jaddou HY, Bateiha AM, Ajlouni KM. Prevalence, awareness and management of hypertension in a recently urbanised community, eastern Jordan. J Hum Hypertens. 2000; 14: 497-501. [18] Jaddou HY, Batiehah AM, Ajlouni KM. Prevalence and associated factors of hypertension: results from a three community-based survey, Jordan. J Hum Hypertens 1996; 10: 815-821. [19] Shipp ML. Awareness status and prevalence of hypertension in a group of urban Haitians: findings of a population-based survey. Ethn Dis 2001; 11: 419-430. [20] Trenkwalder P, Ruland D, Stender M, Gebhard J, Trenkwalder C, Lydtin H, et al. Prevalence, awareness, treatment and control of hypertension in a population over the age of 65 years: results from the Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly (STEPHY). J Hypertens 1994; 12: 709-716. [21] Singh S, Shankar R, Singh GP. Prevalence and Associated Risk Factors of Hypertension: A Cross-Sectional Study in Urban Varanasi. Int J Hypertens. 2017; 2017: 5491838. doi: 10.1155/2017/5491838. Epub 2017 Dec 3. PMID: 29348933; PMCID: PMC5733954. [22] Asai Y, Ishikawa S, Kayaba K, Goto T, Nago N, Kario K, et al. Prevalence, awareness, treatment, and control of hypertension in Japanese rural communities. Nippon Koshu Eisei Zasshi 2001; 48: 827-836. [abstract]. [23] Cifkova R, Skodova Z, Lanska V, Adamkova V, Novozamska E, Petrzilkova Z, et al. Trends in blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2000/01. J Hypertens 2004; 22: 1479-1485. [24] Gu DF, Jiang H, Wu XG, Reynolds K, Gan WQ, Liu DH, et al. Prevalence, awareness, treatment and control of hypertension in Chinese adults. Zhonghua Yu Fang Yi Xue Za Zhi 2003; 37: 84-89. [abstract]. [25] Jo I, Ahn Y, Lee J, Shin KR, Lee HK, Shin C. Prevalence, awareness, treatment, control and risk factors of hypertension in Korea: the Ansan study. J Hypertens 2001; 19: 1523-1532.